Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
HTGMQ
HTG Molecular Diagnostics
$0.00
$0.00
$0.02
N/A2.671,626 shsN/A
IsoPlexis Co. stock logo
ISO
IsoPlexis
$0.76
$0.86
$0.60
$5.10
$30.28M1.3268,375 shsN/A
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
$0.02
$0.10
$0.01
$6.17
$40K2.896,394 shs2 shs
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
$1.50
$1.43
$1.04
$9.35
$2.73M1.32,370 shs4 shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
HTGMQ
HTG Molecular Diagnostics
0.00%0.00%0.00%0.00%-93.33%
IsoPlexis Co. stock logo
ISO
IsoPlexis
0.00%0.00%0.00%0.00%0.00%
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
0.00%0.00%-92.67%+91.30%-99.48%
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
0.00%0.00%+4.90%-6.25%-67.03%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
HTGMQ
HTG Molecular Diagnostics
N/AN/AN/AN/AN/AN/AN/AN/A
IsoPlexis Co. stock logo
ISO
IsoPlexis
N/AN/AN/AN/AN/AN/AN/AN/A
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
N/AN/AN/AN/AN/AN/AN/AN/A
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
HTGMQ
HTG Molecular Diagnostics
0.00
N/AN/AN/A
IsoPlexis Co. stock logo
ISO
IsoPlexis
0.00
N/AN/AN/A
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
0.00
N/AN/AN/A
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
HTGMQ
HTG Molecular Diagnostics
$6.37M0.00N/AN/AN/ANaN
IsoPlexis Co. stock logo
ISO
IsoPlexis
$16.76M1.81N/AN/A$1.04 per share0.73
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
$225.09M0.00N/AN/A$0.14 per share0.16
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
$300K9.12N/AN/A$37.95 per share0.04
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
HTGMQ
HTG Molecular Diagnostics
-$21.59MN/A0.00N/AN/AN/AN/AN/AN/A
IsoPlexis Co. stock logo
ISO
IsoPlexis
-$106M-$2.70N/AN/AN/A-632.41%-127.86%-71.41%N/A
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
-$47.72M-$28.20N/AN/A-336.59%N/A-61.89%N/A
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
-$62.01M-$28.02N/AN/AN/A-79.74%-57.16%8/18/2025 (Estimated)
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
HTGMQ
HTG Molecular Diagnostics
N/AN/AN/AN/AN/A
IsoPlexis Co. stock logo
ISO
IsoPlexis
N/AN/AN/AN/AN/A
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
N/AN/AN/AN/AN/A
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
HTGMQ
HTG Molecular Diagnostics
N/AN/AN/A
IsoPlexis Co. stock logo
ISO
IsoPlexis
1.12
4.06
2.50
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
N/A
1.23
1.06
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
N/A
7.76
7.76

Institutional Ownership

CompanyInstitutional Ownership
HTGMQ
HTG Molecular Diagnostics
N/A
IsoPlexis Co. stock logo
ISO
IsoPlexis
44.91%
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
37.63%
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
43.77%

Insider Ownership

CompanyInsider Ownership
HTGMQ
HTG Molecular Diagnostics
2.60%
IsoPlexis Co. stock logo
ISO
IsoPlexis
6.40%
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
24.50%
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
46.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
HTGMQ
HTG Molecular Diagnostics
902.21 million2.16 millionNot Optionable
IsoPlexis Co. stock logo
ISO
IsoPlexis
45939.76 million37.22 millionNot Optionable
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
2001.80 million1.36 millionOptionable
Talis Biomedical Co. stock logo
TLIS
Talis Biomedical
2601.82 million984,000No Data

Recent News About These Companies

Talis Biomedical Agrees to Settle Investor Suit for $33 Million
Talis Biomedical Corp Ordinary Shares
Why Is Talis Biomedical (TLIS) Stock Down 52% Today?
(TLIS) Trading Report
Talis Biomedical Corp (TLIS)
Talis Biomedical Corporation (TLIS)
TLIS Feb 2024 2.500 put
LICY, BTAI and HROW among mid-day movers

Media Sentiment Over Time

HTG Molecular Diagnostics NASDAQ:HTGMQ

HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine. The company offers instruments; consumables; and software that automate sample processing and profiles various molecular targets. Its marketed molecular profiling panels include HTG Transcriptome Panel; HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq Oncology Biomarker Panel; HTG immune response panel; and HTG mouse mRNA tumor response panel. The company distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona. On June 5, 2023, HTG Molecular Diagnostics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

IsoPlexis stock logo

IsoPlexis NASDAQ:ISO

IsoPlexis Corporation, a life sciences company, provides solutions for the development of curative medicines and personalized therapeutics in the United States, Canada, the United Kingdom, Belgium, France, the Czech Republic, Spain, Germany, Sweden, Italy, Israel, Switzerland, China and Taiwan, Singapore, Japan, Australia, and Korea. The company offers single cell proteomics platform, including instruments, chip consumables, and software that provides an end-to-end solution to view of protein function at an individual cellular level. It provides IsoLight and IsoSpark instruments; IsoCode chips that offer multiplexed chip solutions for single cell functional proteomics; CodePlex chips that provide multiplexed solutions for ultra-low volume bulk samples; and IsoSpeak software that offers dimensional data and automates analysis with an intuitive push button user interface to deliver same day single cell and bulk proteome visualizations, as well as research support and services, and post-warranty services. The company was incorporated in 2013 and is based in Branford, Connecticut.

Telesis Bio stock logo

Telesis Bio NASDAQ:TBIO

$0.02 0.00 (0.00%)
As of 08/6/2025

Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits, which contains building blocks and reagents, including proprietary Gibson assembly branded reagents for specific synthetic biology workflow applications. It also provides BioXp Select kits that offers to use non-telesis bio DNA while using the BioXp system to perform synthetic biology workflow applications, such as cloning, mRNA generation from plasmid, and cell free amplification; BioXp Next Generation Sequencing kits, which contains reagents to go from DNA or RNA to a sequencer-ready library; Benchtop reagents that contains the reagents to proceed specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and custom Gibson short oligo ligation assembly enzymatic DNA synthesis solutions, which is designed to construct synthetic DNA, RNA, and proteins for development of mRNA-based vaccines, diagnostics, therapeutics, and personalized medicines. The company serves its products to government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as Codex DNA, Inc. and changed its name to Telesis Bio Inc. in November 2022. Telesis Bio, Inc. was incorporated in 2011 and is headquartered in San Diego, California.

Talis Biomedical stock logo

Talis Biomedical NASDAQ:TLIS

$1.50 0.00 (0.00%)
As of 08/7/2025

Talis Biomedical Corporation operates as a molecular diagnostic company, focusing on developing medical devices for infectious diseases and other conditions at the point of care in the United States. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Chicago, Illinois.